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Resistant starch (RS), a non-viscous dietary fibre, may have postprandial effects on appetite regulation and metabolism, although the exact effects
and mechanisms are unknown. An acute randomised, single-blind crossover study, aimed to determine the effects of consumption of 48 g RS on
appetite compared to energy and available carbohydrate-matched placebo. Twenty young healthy adult males consumed either 48 g RS or the
placebo divided equally between two mixed meals on two separate occasions. Effects on appetite were assessed, using an ad libitum test meal
and 24-h diet diaries for energy intake, and using visual analogue scales for subjective measures. Changes to postprandial glucose, insulin and
C-peptide were also assessed. There was a significantly lower energy intake following the RS supplement compared to the placebo supplement
at both the ad libitum test meal (5241 (SEM 313) v. 5606 (SEM 345) kJ, P¼0·033) and over the 24 h (12 603 (SEM 519) v. 13 949 (SEM 755) kJ,
P¼0·044). However, there was no associated effect on subjective appetite measures. Postprandial plasma glucose concentrations were not signi-
ficantly different between supplements, but there was a significantly lower postprandial insulin response following the RS supplement (P¼0·029).
The corresponding C-peptide concentrations were not significantly different, although the ratio of C-peptide to insulin was higher following the
RS supplement compared to placebo (P¼0·059). These results suggest that consumption of 48 g RS, over a 24-h period, may be useful in the
management of the metabolic syndrome and appetite. Further studies are required to determine the exact mechanisms.
Fibre: Appetite: Postprandial insulin
The incidence of obesity has increased over recent years and
has reached an epidemic extent(1); this is also associated
with other health issues such as an increased prevalence of
insulin resistance and type 2 diabetes. Various strategies
have been investigated to determine how this problem could
be tackled and to prevent a further increase in body weight
and the associated conditions. These strategies include inves-
tigations into individuals’ diets and specific dietary com-
ponents that could be altered to subsequently impact on
weight, insulin resistance and type 2 diabetes. One such com-
ponent is dietary fibre. This diverse group of carbohydrates
has been proposed to increase satiety(2) and therefore may
have a beneficial role in weight management. Dietary fibre
may increase satiety by several mechanisms and different
fibres may exert their effects by different means although
the specific processes are not known. Proposed mechanisms
include the lower energy density of fibre foods, the impact
of fibre on delaying gastric emptying, which subsequently
could prolong the feeling of fullness, and fibre slowing
glucose absorption, which may prolong satiety(3). There is
also evidence to suggest that dietary fibres may influence
insulin sensitivity(4) independently to any effects on appetite.
Resistant starch (RS), a fermentable carbohydrate, has been
proposed to have properties similar to dietary fibre(5) and
therefore could also affect satiety and exert a beneficial role
in weight regulation. However, as RS is a non-viscous fibre
and is not thought to affect gastric emptying or the absorption
of nutrients(6), the effects on satiety, if indeed there are any,
are unclear. Use of RS may be a more advantageous means
of increasing fibre intake compared to traditional fibres, as it
is easy to incorporate into everyday foods(7) without adverse
alterations to either taste or texture(8).
There are few studies that have investigated the effects of
including RS into the diet and the consequent effects on
appetite. Animal studies show consistent positive effects
on appetite regulation and insulin sensitivity; however, data
in human studies are mixed(9). In particular, there are no cur-
rent studies in human subjects that have explored the effects
on appetite of including RS in mixed meals when compared
to energy and carbohydrate-matched placebo. Of the four
classifications of RS, the majority of studies looking at effects
on appetite have used type 2, which are intrinsically resistant,
and type 3, which are retrograded starches.
The postprandial effects of consumption of RS are also not
known; however, as a non-viscous fibre, it would not be
predicted to affect glucose absorption. Nevertheless, it has
been shown in a recent study that short-term consumption of
RS type 2 improves postprandial glucose metabolism in
healthy individuals(6).
The present study therefore aimed to investigate the acute
effects of including 48 g of RS type 2 on energy intake,
subjective measures of appetite and changes to postprandial
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glucose and insulin, compared to a placebo supplement in a
randomised, single-blind balanced crossover, in which the
48 g were divided equally between breakfast and lunch
(providing 24 g at each meal) and consumed as part of these
mixed meals.
Experimental methods
Subjects
Twenty young, healthy, adult males, aged 19–31 years, with a
mean BMI 23·2 (SEM 0·65) kg/m2 (Table 1) participated in the
study. Subjects had no history of gastrointestinal disease or
endocrine disorders and were weight stable for at least the pre-
ceding 3 months. Highly restrained eaters, identified by the
Dutch Eating Behaviour Questionnaire(10), were excluded
from the study. The participants included in the study had a
mean score of 2·1 (SEM 0·2) on the restraint scale, 1·98
(SEM 0·1) on the emotional scale and 3·1 (SEM 0·1) on the
external eating scale. The present study was conducted accord-
ing to the guidelines laid down in the Declaration of Helsinki
and all procedures involving human subjects were approved
by the University of Surrey’s Ethics Committee; written,
informed consent was obtained from all subjects.
Study design
Subjects attended the investigation unit after an overnight fast,
on two occasions, at least 1 week apart, when they consumed
either the RS supplement or the placebo supplement within the
test breakfast and lunch meals, which provided 24 g RS at
breakfast and 24 g RS at lunch on the RS leg. Blood samples
and appetite ratings, including desire for different foods,
(measured using 100 mm visual analogue scales, as described
by Flint et al. (11)), were taken every 30 min for the 7-h inter-
vention period. The participants remained in the investigation
unit for the duration of the study and were required to
minimise activity.
On the day before each study day, each participant
consumed an identical evening meal and was required to
avoid alcohol, caffeine and strenuous exercise for at least
24 h before the study.
On the two separate days, subjects received either 80 g
Hi-Maizew 260 product (60 % RS type 2 and 40 % rapidly
digestible starch (RDS)) which therefore provided 48 g RS
and 32 g RDS (as measured by The Association of Official
Analytical Chemists for total dietary fiber method 991·43) or
32 g of the placebo Amiocaw (100 % RDS) providing 32 g
RDS. Both the supplements were supplied by the National
Starch Company, LLC (Bridgewater, NJ, USA) and were
incorporated into a flavoured mousse. Available carbohydrate
from the RDS portion of both supplements was exactly
matched on both occasions, giving meals with comparable
glycaemic load. The mousses were of a similar taste and
texture and were consumed as part of the test breakfast and
lunch meals. Forty grams of the Hi-Maize supplement were
the highest quantity that could be added to one mousse portion
without adverse effects on taste or texture and a similar high
level of RS has been given in other studies without adverse
gastrointestinal effects. Subjects were able to choose their
preferred flavour of mousse from three choices to enhance
compliance, but consumed the same flavour on both visits.
Subjects were cannulated; two fasting blood samples were
taken, one 15 min before breakfast and the other just before
breakfast, which was served at time zero. The breakfast on
both days was of a standardised portion size and consisted
of Rice Krispiesw (Kellogg’s, Manchester, UK) with semi-
skimmed milk and one portion of the mousse which contained
the test carbohydrate; the energy and macronutrient compo-
sition of this meal is shown in Table 2.
Lunch, containing the second half of the test carbohydrate,
was served at 180 min, to allow the participants to receive
their meals at times similar to their habitual pattern. The
lunch meal was either ham or cheese sandwiches (the same
filling was consumed on each study day by the same subject),
crisps, an orange flavoured drink and one portion of the
mousse with the supplement. All food was weighed before
being given to the subjects and on the first visit subjects
were able to regulate their intake from the offered food
(except for the mousse which they were required to fully con-
sume on all visits). Whatever was not consumed was weighed,
and the subjects were then required to consume an identical
amount on the subsequent visit to ensure the energy and
macronutrient intake was identical with only the presence of
the RS differing. A similar study design has been used
successfully in previous studies(12). The mean values for the
amounts consumed at lunch are shown in Table 2.
At the end of the intervention (420 min) participants were
placed in individual areas and provided with a large pre-
weighed ad libitum homogenous test meal, in excess of
normal portion sizes (the whole dish provided: 9765 kJ
energy, 81·5 g protein; 339·1 g carbohydrate; 70·0 g fat;
15·9 g fibre). Subjects were instructed to consume freely
until comfortably full and then the leftovers were weighed.
The subjects were informed that they could take home any
leftover test meal in order to prevent over-consumption.
The ad libitum test meal was a pasta-based meal which was
made to a standard recipe with standard cooking times; how-
ever, while the energy content was identical on both visits, the
energy density per gram would have varied depending on
the amount of water absorbed during cooking. Therefore,
this was taken into consideration when the energy intake
was calculated for each visit.
Table 1. Subject measurements taken on the morning of the first study
visit
(Mean values with their standard errors for twenty male subjects)
Measurement Mean SEM
Age (years) 25·8 0·82
Height (cm) 181·2 1·62
Weight (kg) 76·2 2·48
BMI (kg/m2) 23·2 0·65
Waist circumference (cm) 85·5 2·07
Hip circumference (cm) 97·4 1·42
Body fat (%)* 15·0 1·17
Systolic blood pressure (mmHg)† 120·8 1·69
Diastolic blood pressure (mmHg)† 74·4 2·16
* Measured by bioimpedance (Tanita TBF-300, Tanita, UK).
† Mean of three readings taken with the subject in a sitting position, measured by
an automatic blood pressure cuff (Omron MX3 Plus; Omron Healthcare Europe,
Kruisweg, UK).
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Overall 24-h intake on the study days was assessed from
weighed intakes from the breakfast, lunch and ad libitum
dinner provided and from diet diaries completed during the
late evening by subjects after they had left the unit. All dietary
analysis was performed using WinDiets Professional Version
program (Robert Gordon University, Aberdeen, UK). Bowel
habit diaries were completed on the day of the study and the
following day for assessment of gastrointestinal tolerance.
Biochemistry
Whole blood for glucose analysis was collected into sodium
oxalate tubes, for insulin analysis into potassium EDTA tubes
and for C-peptide analysis into potassium EDTA tubes with
200 kallikrein inhibiting units (KIU) aprotinin per ml of
whole blood (Trasylol; Bayer, Newbury, UK). All samples
were centrifuged for 10 min at 3000 rpm and then plasma ali-
quots were stored at 2208C until batch analysis to reduce
inter-assay variation. Plasma glucose was measured enzymati-
cally using a commercially available kit (Instrumentation
Laboratory, Warrington, UK) for the ILab650 (Instrumentation
Laboratory) and the inter-assay variation was ,2 %. Concen-
trations of plasma insulin and C-peptide were measured by
RIA with commercially available kits (Millipore; Watford,
UK). The sensitivity of the insulin assay was 12 pmol/l
(2mU/ml) and for the C-peptide assay was 0·1 ng/ml, with an
inter- and intra-assay variation of ,10 %.
Calculations and statistical analysis
Fasted insulin sensitivity and b-cell function (homeostasis
model assessment (HOMA) % S and HOMA % B, respectively)
were assessed by HOMA(13) at the beginning of each study
morning; while postprandial insulin sensitivity was assessed
using the minimal model method described by Caumo
et al. (14).
Area under the curve was calculated for glucose, insulin and
C-peptide, using the trapezoid method. The ratio of C-peptide
to insulin was calculated using the area under the curve for
2 h after each meal for both measures and used as a marker
of hepatic insulin clearance. Time course data were analysed
by repeated measures ANOVA. The data were normally
distributed and paired t tests were used to compare between
the groups. Statistical analyses were carried out using SPSS
version 12.0.1 for Windows (SPSS, Inc., Chicago, IL, USA),
with significance assumed as P,0·05. All the results are
means with their standard errors.
Results
Both the supplements were well tolerated by the subjects with
no adverse gastrointestinal effects reported on the day of the
study or the following day.
The fasting insulin sensitivity and b-cell function (assessed
by the homeostatic model assessment(13)) were not signifi-
cantly different at the start of each of the study days
(Table 3), which confirms that the subjects were in a similar
metabolic state at the start of each study day.
Energy and macronutrient intake
Supplementation with 48 g RS over two meals resulted in a
significantly lower energy intake, 5241 (SEM 313 kJ) at the
offered ad libitum test meal compared to the energy intake
seen with the placebo, 5606 (SEM 345 kJ; P¼0·033).
Over the whole 24-h period there was also a significantly
lower energy intake following the 48 g RS supplement
compared to the placebo supplement, from 12 603 to
13 949 kJ (P¼0·044; Table 4). With the RS leg the mean
energy intake was 104 % of calculated habitual energy
requirements (calculated with the Schofield equation(15) and
a moderate activity level of 1·6 for all subjects) compared to
116 % for the placebo leg.
The lower 24-h energy intake appeared to be mainly due to
a significantly lower fat intake, 13·3 g lower, following the RS
supplement compared to the placebo (Table 4). The dietary
fibre intake during this 24-h period was significantly different
Table 3. Indices of insulin sensitivity following consumption of 48 g resistant starch (RS) or placebo*
(Mean values with their standard errors in twenty healthy, young adult males)
RS Placebo
Mean SEM Mean SEM P
HOMA % S 95·9 7·5 97·0 8·9 NS
HOMA % B 105·3 5·9 111·4 9·8 NS
C-peptide:insulin AUC 0–300 min 6·69 0·37 6·13 0·42 0·059
Oral SI breakfast (dl/kg min per mU ml) 3·36 £ 1023 0·44 £ 1023 8·50 £ 1023 5·58 £ 1023 NS
Oral SI lunch (dl/kg min per mU ml) 5·65 £ 1023 1·11 £ 1023 4·43 £ 1023 0·63 £ 1023 NS
HOMA % S, fasted oral insulin sensitivity, assessed by homeostasis model assessment; HOMA % B, b-cell function, assessed
by homeostasis model assessment; AUC, area under the curve; SI, oral insulin sensitivity to each meal, calculated with a
minimal model.
* Comparisons were made with a paired samples t test.
Table 2. Nutritional composition of the breakfast and lunch meals
consumed on both study days
(Mean values with their standard errors for twenty subjects)
Breakfast Lunch
Mean SEM Mean SEM
Energy (kJ) 1595 2·7 3865 151·9
Protein (g) 9·6 0·03 35·6 1·54
Carbohydrate (g) 67·2 0·20 111·9 3·36
Fat (g) 7·9 0·03 36·8 2·87
Fibre (g) 0·5 (24·5*) 0·05 5·0 (29·0*) 0·20
* Resistant starch meal only.
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due to the supplementation with 48 g RS, and there did not
appear to be a difference in fibre intake by the subjects once
they left the investigation unit at the end of the postprandial
study period.
Subjective appetite measures
There was no difference in the subjective appetite scores,
measured by the visual analogue scales, for hunger (Fig. 1),
fullness, prospective food consumption, thirst or desire for
different foods (sweet, salty, savoury or fatty foods) between
the two supplements.
Postprandial metabolites
The postprandial glucose concentrations were not significantly
different between the RS supplement and the placebo sup-
plement (Fig. 2(a)).
There was a significantly lower postprandial insulin
response following the RS supplementation compared to the
placebo supplement over the whole acute study period
(P¼0·029; Fig. 2(b)). However, the corresponding C-peptide
concentrations were not significantly different between the
two supplements. Consequently, there was an increase in
molar ratio of C-peptide to insulin as a surrogate marker for
hepatic insulin clearance (Table 3); however, there was no
significant difference in postprandial oral insulin sensitivity
between the two supplements at either meal (Table 3).
Discussion
The present study found that after consumption of 48 g RS
(split equally over the test breakfast and lunch meals), there
was a lower energy intake at both the ad libitum test meal
and over the whole 24-h period, without an associated effect
on subjective appetite ratings; the study also found a signifi-
cant effect of the RS supplement on lowering the postprandial
insulin response. To our knowledge this is the first study
where RS has been provided to participants as part of a
mixed meal and compared to a placebo, where available
carbohydrate and energy load have been matched.
Previous studies investigating the effects of RS on appetite
have replaced proportions of carbohydrate with RS and there-
fore the amount of glycaemic carbohydrate provided has
varied between the supplements which would confound the
interpretation of the results. Indeed, in one study consumption
of RS appeared to cause a reduction in subjective feelings of
satiety(16); however, a limitation of the study was that the RS
and the corresponding 100 % digestible starch were mixed into
fruit syrup drinks as a means of delivering the starches, which
resulted in the two supplement drinks having a different
texture, one liquid and the other semi-solid, with liquids
being known to be less satiating than solid foods(17); this
study also matched the supplements by weight of starch and
therefore the supplements differed in energy and available
carbohydrate content. In another study by de Roos et al. (18)
two types of RS (RS type 2 and RS type 3) were compared
to glucose and, while the supplements were matched for
total carbohydrate content, the proportion of available carbo-
hydrate was lower in both of the RS supplements. The study
also found that after consumption of each product for
1 week, there was little effect of the RS on appetite. Other
studies have investigated the effects on appetite of varying
the amylose to amylopectin ratios. One of these studies
found that immediately after the meal the high level of
amylase was more satisfying than the low amylase but that
Table 4. Total 24-h intake following supplementation with 48 g resistant
starch (RS) or placebo, measured from 24-h diet diaries*
(Mean values with their standard errors for twenty subjects)
RS Placebo
Mean SEM Mean SEM P
Energy (kJ) 12 603 519 13 949 755 0·044
Protein (g) 104·9 5·63 115·3 6·87 NS
Carbohydrate (g) 424·4 18·40 452·6 23·00 NS
Fat (g) 96·7 4·56 110·0 4·79 0·017
Saturated fat (g) 39·2 2·18 45·2 2·37 0·014
Dietary fibre (g) 65·1 0·95 16·7 0·84 ,0·001
* Comparisons were made with a paired samples t test.
Fig. 1. Subjective appetite ratings on a visual analogue scale in response to the question ‘how hungry do you feel?’. Means with their standard errors for twenty healthy,
young adult males after consumption of 48 g resistant starch (RS; X) compared to a placebo (W). - - -, Supplements consumed at the breakfast and lunch meals.
There was no significant difference between the supplements for any of the subjective appetite ratings despite the lower energy intake seen with RS consumption.
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the high amylose was also the least palatable(19). Another
study that varied amylose and amylopectin ratios, found no
significant effect between their treatments on visual analogue
scale ratings(12).
In the present study, on both study days, the participants
consumed more than their estimated requirements (104 %
on the RS leg and 116 % on the placebo leg) and therefore
there was likely to be an element of over-consumption as
the participants were given food and did not have to prepare
it for themselves; however, the individuals still appeared to
over-consume less on the RS leg than on the placebo leg
and this can be directly attributed to the RS as the only differ-
ence between the test meals. However, this over-consumption
may explain why no effects were found in any of the subjec-
tive appetite ratings. The overall 24-h intake was derived from
the weighed food given to participants at the three meals
within the unit and from the reported participant intake later
in the evening, so only a small contribution to total intake
was obtained indirectly, from participant self-reporting.
When using the Goldberg cut-off(20) to identify under-report-
ing none of the participants would have been classified as
under-reporters for either leg of this intervention and so the
results are likely to be representative of true intake. All
meals were based on standard portion sizes rather than set
to BMR, as one of the main outcomes of the study was an
effect on the metabolic response, which would have been
masked if intakes were set to BMR. The only difference
between the two legs, apart from the 48 g of RS, could have
been a small difference in the energy density of the meals
due to the presence of the RS; however, this was minor (for
breakfast and lunch combined the density per gram was
7·2 kJ/g for the RS leg and 7·7 kJ/g for the placebo leg) and
the glycaemic load of the two legs was identical.
The lower energy intake seen in the present study over 24 h
appeared to be mainly explained by a significantly lower fat
intake following the RS supplement. However, the reason
for this lower fat intake is unclear, as the participants did
not report a difference in desire for fatty foods on the subjec-
tive appetite ratings during the postprandial study. This differ-
ence in macronutrient choice following RS consumption
would require further investigation to determine whether it
was an incidental finding or a true effect. There also did not
appear to be an influence of the high RS intake on fibre
intake later in the day; however, there may have been an
effect on the following day’s fibre intake that was not moni-
tored in the present study.
Although in the present study a reduced energy intake was
found following consumption of the RS supplement, it is not
possible from the design of the present study to determine
exactly what the mechanisms are for the observed effect on
food intake. However, as the main effect on food intake
appeared to occur at the ad libitum dinner and then later in
the day once the participants had left the unit, a possible
mechanism could be the fermentation in the colon by colonic
microflora and the subsequent effects of SCFA, which has
been hypothesised as a mechanism for the effects of fibre on
appetite(3).
While the metabolism of SCFA may result in potential
additional energy being provided to the body, this was not
accounted for in the present study and no value was assigned
for the fermentation of the RS. The actual amount delivered to
each participant is likely to vary, dependant on the extent of
fermentation and metabolism within the colon(21) and vari-
ations in individuals’ gut transit time(22), as well as a loss to
the faeces of a proportion of the ingested RS and the SCFA
produced. Published works have stated an energy value of
8 kJ/g for Hi-Maizew 260(23) accounting for SCFA metabolism
compared to the 16 kJ/g for the placebo. In the present study,
we matched the supplements by glycaemic load as the largest
confounder to the glycaemic response. When taking into con-
sideration the amounts of each supplement given this would
have resulted in maximal energy doses of 640 kJ for the RS
and 512 kJ for the placebo, with a difference of only 128 kJ.
This therefore does not account for the full difference in
energy intake observed in the study over the 24-h period
which was 1346 kJ.
It is possible that the increase in production of SCFA may
consequently increase production of anorexigenic hormones
from the colon, such as peptide YY(24,25). However, so far
the only evidence of an effect of RS on these hormones, par-
ticularly peptide YY and glucagon-like peptide, has been
shown in rodent studies(26 – 28), which are, in terms of the gas-
trointestinal tract, anatomically different(29) to human subjects.
Human studies which have measured gastrointestinal peptides
have found no effect of fibre feeding(6,16).
As insulin and C-peptide are co-secreted, the lower post-
prandial insulin concentration detected was likely to be due
to increased hepatic insulin clearance, as there was a trend
towards significance between the two supplements for the
molar ratio of C-peptide to insulin. An increase in hepatic
insulin clearance has previously been reported following RS
intake over 24 h(30). It has been proposed that the increase in
Fig. 2. Postprandial plasma glucose (a) and insulin concentrations (b) after
consumption of 48 g resistant starch (RS; X) compared to a placebo (W).
Means with their standard errors for twenty healthy, young adult males. - - -,
Supplements consumed at the breakfast and lunch meals. There was no sig-
nificant difference between the supplements for the glucose concentrations.
However, the plasma insulin response was significantly lower (P¼0·029)
following RS supplementation. Comparisons made with repeated measures
ANOVA.
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production of SCFA and their exposure to the liver may ulti-
mately be responsible for the increase in insulin clearance.
The lower energy intake seen in the present study following
RS consumption as part of a mixed meal could have beneficial
implications in weight management and, potentially, weight
loss; however, further studies are required to confirm whether
a similar finding is seen in other population groups such as the
overweight or obese, and to determine the actual mechanisms
for the effect. Although the dose in the present study was well
tolerated over the one day of the study and a lower energy
intake was observed, further investigations are needed to
establish whether the dose has similar effects when ingested
chronically. A lower postprandial insulin response was also
observed which could be explained by an increase in hepatic
insulin clearance. Increased intakes of RS in the diet may
therefore have beneficial implications in weight management.
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